HUT69390A - Controlled, sustained release delivery system for smoking cessation - Google Patents

Controlled, sustained release delivery system for smoking cessation Download PDF

Info

Publication number
HUT69390A
HUT69390A HU9303146A HU9303146A HUT69390A HU T69390 A HUT69390 A HU T69390A HU 9303146 A HU9303146 A HU 9303146A HU 9303146 A HU9303146 A HU 9303146A HU T69390 A HUT69390 A HU T69390A
Authority
HU
Hungary
Prior art keywords
lobelin
kit
drug delivery
delivery system
biodegradable polymer
Prior art date
Application number
HU9303146A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9303146D0 (en
Inventor
Judith A Kitchell
Indu A Muni
Yvonne N Boyer
Original Assignee
Dynagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynagen Inc filed Critical Dynagen Inc
Publication of HU9303146D0 publication Critical patent/HU9303146D0/hu
Publication of HUT69390A publication Critical patent/HUT69390A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HU9303146A 1991-05-07 1992-05-07 Controlled, sustained release delivery system for smoking cessation HUT69390A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69663791A 1991-05-07 1991-05-07

Publications (2)

Publication Number Publication Date
HU9303146D0 HU9303146D0 (en) 1994-01-28
HUT69390A true HUT69390A (en) 1995-09-28

Family

ID=24797928

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9303146A HUT69390A (en) 1991-05-07 1992-05-07 Controlled, sustained release delivery system for smoking cessation

Country Status (8)

Country Link
EP (1) EP0720478A1 (fi)
JP (1) JPH06507416A (fi)
AU (2) AU2154892A (fi)
CA (1) CA2102507A1 (fi)
FI (1) FI934919A (fi)
HU (1) HUT69390A (fi)
NO (1) NO933971L (fi)
WO (2) WO1992019226A1 (fi)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
EP0633907A1 (en) * 1992-03-30 1995-01-18 Alza Corporation Additives for bioerodible polymers to regulate degradation
MX9301823A (es) * 1992-03-30 1994-01-31 Alza Corp Composicion para el suministro de liberacion controlado de un agente biologicamente activo.
US5612357A (en) * 1992-05-18 1997-03-18 Pharmaco Behavioral Associates, Inc. Use of cotinine to assist in the cessation of tobacco smoking
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
SE519940C2 (sv) * 1994-06-03 2003-04-29 Carl Dahlborn Ab Implanterbar anordning
EP0782445B1 (en) * 1994-09-19 2002-03-13 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU748804B2 (en) * 1995-07-20 2002-06-13 Smithkline Beecham Plc Paroxetine controlled release compositions
EP0850051A2 (en) * 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
DE19642043A1 (de) 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
EP1393724B1 (en) * 1996-07-15 2006-04-05 Alza Corporation Novel formulations for the transdermal administration of fluoxetine
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
ES2227707T3 (es) * 1996-07-15 2005-04-01 Alza Corporation Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina.
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
US5830904A (en) * 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
WO1998053815A1 (en) * 1997-05-30 1998-12-03 Minnesota Mining And Manufacturing Company Transdermal drug delivery device for the delivery of tropisetron or granisetron
US6120806A (en) * 1997-06-25 2000-09-19 Whitmire; David R. Oral formulations for controlled release of alcohol deterrents
ES2141024B1 (es) * 1997-10-03 2000-10-16 Manzanares Jesus Mari Gonzalez Preparado de accion antinicotinica.
DE19746191C2 (de) 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US7098206B2 (en) 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
WO1999038503A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
CA2318738A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7658998B2 (en) 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
ATE531374T1 (de) 2004-04-15 2011-11-15 Alkermes Inc Vorrichtung auf polymerbasis mit verzögerter freisetzung
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4917676A (en) * 1986-11-20 1990-04-17 Ciba-Geigy Corporation User-activated transdermal therapeutic system
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
CA1273878A (en) * 1987-01-15 1990-09-11 Richard Philip Moody Nicotine-containing preparation for transdermal administration
JP2677371B2 (ja) * 1988-01-30 1997-11-17 帝國製薬株式会社 含水性喫煙代用貼付剤
EP0432945A1 (en) * 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction

Also Published As

Publication number Publication date
EP0720478A1 (en) 1996-07-10
AU2154892A (en) 1992-12-21
HU9303146D0 (en) 1994-01-28
FI934919A (fi) 1993-12-17
JPH06507416A (ja) 1994-08-25
WO1992019226A1 (en) 1992-11-12
FI934919A0 (fi) 1993-11-05
WO1992019241A1 (en) 1992-11-12
NO933971D0 (no) 1993-11-03
NO933971L (no) 1994-01-07
AU2016092A (en) 1992-12-21
AU657973B2 (en) 1995-03-30
CA2102507A1 (en) 1992-11-08

Similar Documents

Publication Publication Date Title
HUT69390A (en) Controlled, sustained release delivery system for smoking cessation
US5536503A (en) Controlled, sustained release delivery system for smoking cessation
US5486362A (en) Controlled, sustained release delivery system for treating drug dependency
US20200405630A1 (en) Method and device for transdermal delivery of parathyroid hormone using a microprojection array
KR102457026B1 (ko) 입을 통한 연속적 약물 전달
KR102014565B1 (ko) 부프레노르핀을 포함하는 경피 전달 시스템
JP2019063574A5 (fi)
RU2428186C2 (ru) Лекарственная композиция для чрескожной абсорбции, изделие, сохраняющее лекарственную композицию, и содержащий ее препарат для чрескожной абсорбции
KR101606944B1 (ko) 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법
CN104661648B (zh) 阿片样物质制剂
JPH04507256A (ja) 二相性経皮薬物供給デバイス
Cleary Transdermal delivery systems: a medical rationale
IL96276A (en) Transdermal administration system of 2-amino-N-6-propylamino - 4,5,6,7-tetrahydrobenzothiazole
TWI343263B (en) Patches for mucosa of oral cavity containing fentanyl
MX2007006833A (es) Composiciones y metodos para tratar condiciones de la unidad de una.
HU230374B1 (hu) Gyógyszerkészítmény buprenorfin hosszan tartó analgetikus hatásának kiváltására
D’Souza et al. Nasal insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies
TW200812642A (en) Compositions and methods for treating conditions of the nail unit
JP2011515485A (ja) ロフェキシジンを経粘膜送達するための組成物およびその方法
JPH04506958A (ja) リスリドの経皮投与
FR2582511A1 (fr) Systeme d'application endonasal
FR3087107A1 (fr) Compositions, systèmes, kits et méthodes d'ablation neurale
DE10018834A1 (de) Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
TW201141477A (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
JP2008519810A (ja) 顔面紅潮の治療のためのｓミルタザピン

Legal Events

Date Code Title Description
DFD9 Temporary prot. cancelled due to non-payment of fee